The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT)

被引：0
作者：
Ko, Jenny J.
Xie, Wanling
Heng, Daniel Yick Chin
Kroeger, Nils
Lee, Jae-Lyun
Rini, Brian I.
Knox, Jennifer J.
Bjarnason, Georg A.
Harshman, Lauren Christine
Pal, Sumanta Kumar
Yuasa, Takeshi
Smoragiewicz, Martin
Donskov, Frede
Bamias, Aristotelis
Wood, Lori
Ernst, D. Scott
Agarwal, Neeraj
Vaishampayan, Ulka N.
Rha, Sun Young
Choueiri, Toni K.
机构：
[1] Tom Baker Canc Clin, Calgary, AB, Canada
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[4] Univ Med Greifswald, Dept Urol, Greifswald, Germany
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[6] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[7] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med, Toronto, ON, Canada
[8] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[9] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[10] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[11] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Urol, Tokyo, Japan
[12] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[13] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark
[14] Alexandra Peripheral Gen Hosp, Athens, Greece
[15] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[16] London Reg Canc Ctr, London, ON N6A 4L6, Canada
[17] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[18] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[19] Yonsei Univ, Coll Med, Seoul, South Korea
[20] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.398
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
398
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)
    Dudani, Shaan
    de Velasco, Guillermo
    Wells, Connor
    Gan, Chun Loo
    Donskov, Frede
    Porta, Camillo
    Fraccon, Anna
    Pasini, Felice
    Hansen, Aaron Richard
    Bjarnason, Georg A.
    Beuselinck, Benoit
    Pal, Sumanta K.
    Hotte, Sebastien J.
    Lalani, Aly-Khan A.
    Yuasa, Takeshi
    Kanesvaran, Ravindran
    Reaume, M. Neil
    Canil, Christina M.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [22] First-line (1L) immuno-oncology (10) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Dudani, Shaan
    Graham, Jeffrey
    Wells, Connor
    Pal, Sumanta K.
    Dizman, Nazli
    Donskov, Frede
    Bjarnason, Georg A.
    Hansen, Aaron Richard
    Iafolla, Marco Adelmo James
    Vaishampayan, Ulka N.
    Porta, Camillo
    Beuselinck, Benoit
    Yan, Flora
    Wood, Lori
    Liow, Elizabeth Chien Hern
    Kollmannsberger, Christian K.
    Yuasa, Takeshi
    Zhang, Chiyuan A.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [23] First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
    Ruiz-Morales, Jose Manuel
    Swierkowski, Marcin
    Wells, J. Connor
    Fraccon, Anna Paola
    Pasini, Felice
    Donskov, Frede
    Bjarnason, Georg A.
    Lee, Jae-Lyun
    Sim, Hao-Wen
    Sliwczynsk, Andrzej
    Ptak-Chmielewska, Aneta
    Teter, Zbigniew
    Beuselinck, Benoit
    Wood, Lori A.
    Yuasa, Takeshi
    Pezaro, Carmel
    Rini, Brian I.
    Szczylik, Cezary
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    EUROPEAN JOURNAL OF CANCER, 2016, 65 : 102 - 108
  • [24] Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).
    Ernst, Matthew Scott
    Navani, Vishal
    Wells, J. Connor
    Donskov, Frede
    Basappa, Naveen S.
    Labaki, Chris
    Pal, Sumanta K.
    Meza, Luis A.
    Wood, Lori
    Ernst, D. Scott
    Szabados, Bernadett
    Mckay, Rana R.
    Parnis, Francis
    Suarez, Cristina
    Yuasa, Takeshi
    Kapoor, Anil
    Alva, Ajjai Shivaram
    Bjarnason, Georg A.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [25] Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings
    Tanaka, Nobuyuki
    Mizuno, Ryuichi
    Shirotake, Suguru
    Ito, Keiichi
    Yasumizu, Yota
    Masunaga, Ayako
    Ito, Yujiro
    Miyazaki, Yasumasa
    Hagiwara, Masayuki
    Kanao, Kent
    Mikami, Shuji
    Nakagawa, Ken
    Momma, Tetsuo
    Masuda, Takeshi
    Asano, Tomohiko
    Oyama, Masafumi
    Oya, Mototsugu
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (07) : 293.e17 - 293.e25
  • [26] A new prognostic model of survival in second-line targeted therapy (TT) for metastatic renal cell carcinoma (mRCC).
    Derosa, Lisa
    Bayar, Mohamed Amine
    Albiges, Laurence
    Massard, Christophe
    Loriot, Yohann
    Fizazi, Karim
    Le Teuff, Gwenael
    Escudier, Bernard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Graham, Jeffrey
    Wells, Connor
    Donskov, Frede
    Lee, Jae-Lyun
    Fraccon, Anna Paola
    Pasini, Felice
    Porta, Camillo
    Bowman, I. Alex
    Bjarnason, Georg A.
    Ernst, D. Scott
    Rha, Sun Young
    Beuselinck, Benoit
    Hansen, Aaron Richard
    North, Scott A.
    Kollmannsberger, Christian K.
    Wood, Lori
    Vaishampayan, Ulka N.
    Pal, Sumanta K.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [28] Re: First-Line Sunitinib versus Pazopanib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
    Laguna, M. Pilar
    JOURNAL OF UROLOGY, 2017, 197 (03) : 603 - 603
  • [29] Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with first-line (1L) therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Takemura, Kosuke
    Graham, Jeffrey
    Maj, David
    Zarba, Martin
    Wells, Connor
    Chehade, Razane El Hajj
    Eid, Marc
    Saad, Eddy
    Saliby, Renee Maria
    Lee, Jae Lyun
    Donskov, Frede
    Beuselinck, Benoit
    Jude, Evon
    McKay, Rana R.
    Basappa, Naveen S.
    Pal, Sumanta Kumar
    Porta, Camillo
    Agarwal, Neeraj
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [30] New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC)
    Derosa, L.
    Guida, A.
    Albiges, L.
    Massard, C.
    Loriot, Y.
    Galli, L.
    Fizazi, K.
    Escudier, B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S478 - S479
12345